MTRC is pleased to announce the release of its latest White Paper: "Reimbursement Pathways for Companion Diagnostic (CDx) Tests in Europe". This document provides a comprehensive overview of the reimbursement landscape for CDx tests in five largest European countries: England, France, Germany, Italy, and Spain.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Goetz et al. examined where EUnetHTA guidance documents require further methodological clarity in light of the upcoming EU HTA regulation. Through a systematic document review and structured stakeholder discussions conducted in Austria, the authors identified 32 key areas in need of refinement ‒ primarily related to evidence synthesis and eligibility criteria. Drawing on established HTA and evidence synthesis handbooks, the authors proposed concrete methodological options, offering actionable insights to support implementation across EU member states.

The French National Authority for Health (HAS) has released new recommendations regarding add-on reimbursement for medical devices and medical aids following the March 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Six favorable opinions were published concerning the registration of new devices or modifying conditions/indications for existing ones in the List of Reimbursable Products and Services (LPPR). The recommendations relate to devices in the fields of cardiovascular, peripheral vascular, endocrine, neuromodulation, and medical aids.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Ali et al. explored practical strategies to reduce the ecological impact of dermatological surgery in the UK, aligning with the National Health Service's commitment to sustainability. The review outlined key system-wide approaches, including reducing overall surgical activity through prevention, promoting research and innovation, and enhancing service management. The authors also highlighted the critical role of managerial policy, procurement practices, and supply chain dynamics in supporting broader national and international sustainability goals.

In March 2025, the National Institute for Health and Care Research (NIHR) in England released four Med Tech-related assessments in its HTA Journal, which concerned the results of the studies provided within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs NICE guidance.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Donovan et al. introduced Cost-IS, a novel tool designed to support the economic evaluation of implementation strategies for digital health solutions. Its development followed a structured, multi-phase approach involving a literature review, expert interviews, and a modified e-Delphi process. A panel of 12 multidisciplinary experts reached a consensus on the instrument’s core design, though additional piloting is required to evaluate its real-world feasibility and generalizability.

In March 2025, the Decision Forum for the "New Methods" framework made a favorable coverage decision for robotic-assisted prostatectomy, hysterectomy, and rectal resection in cancer indications.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Bourke et al. proposed a novel conceptual framework to support Health Technology Assessment (HTA) processes in reflecting the real-world burden on caregivers. Addressing the current gap in HTA practices caused by limited methodological guidance, the authors offer a structured approach to capture caregiving intensity and duration. Their recommendations aim to assist policymakers, researchers, and manufacturers in aligning HTA submissions with a broader societal perspective.

On March 26, 2025, the Law to accelerate the digitalization of the healthcare system (Digital Law, DigiG) came into force.

MTRC is pleased to announce the release of its latest White Paper: "Challenges of HTA and Reimbursement Submissions for Medical Devices". This White Paper explores key challenges in reimbursement and HTA submission processes for medical devices and proposes practical solutions to address them.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to understand the potential scope of our support better. From the week of the 07th of April, we plan to work on 21 projects. Review the complete list of planned activities in this post.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Tanner et al. examined key cross-functional challenges stemming from Joint Scientific Consultations (JSC) and Joint Clinical Assessments (JCA) and how manufacturers should address them in their EU HTAR readiness plans. Conducted through literature review, guidance analysis, and manufacturer insights, the study identified five key cross-functional areas: global asset strategy, non-EU regional readiness, launch sequence evolution, brand perception, and pricing impacts. Given the central role of market access in bringing innovation to patients, the EU HTAR will have far-reaching implications, with early Joint Clinical Assessment reports expected to significantly influence brand strategy, pricing dynamics, and global launch sequencing.